Armour Thyroid and Liver Function: What Women Need to Know

Import from '@/components/mdx'

What Armour Thyroid Is and Why Women Use It

Armour Thyroid is a prescription porcine-derived natural desiccated thyroid extract containing both T4 and T3 in a roughly 4:1 ratio. Levothyroxine (synthetic T4 alone) is the standard first-line treatment for hypothyroidism, but a meaningful subset of women report persistent symptoms on levothyroxine even when their TSH sits in the normal range. That experience drives many to ask about NDT.

Hypothyroidism itself is a women's condition disproportionately. Autoimmune thyroiditis (Hashimoto's disease) affects women 7 to 10 times more frequently than men, and the prevalence of overt hypothyroidism in women over 60 reaches approximately 5 to 8 percent. Add in subclinical hypothyroidism and postpartum thyroiditis and you have a condition that touches virtually every stage of a woman's reproductive life.

Why the Liver Matters in This Conversation

Thyroid hormone is metabolized largely in the liver. The liver converts T4 to active T3 through deiodinase enzymes, conjugates thyroid hormones for biliary excretion, and produces thyroid-binding globulin (TBG), the main carrier protein for circulating thyroid hormones. When thyroid status is off, the liver shows it. When liver status is off, thyroid hormone levels can be misleading. The two systems are tightly linked, and for women, estrogen adds a third variable because estrogen directly stimulates hepatic TBG synthesis, raising total T4 and T3 without necessarily changing free hormone levels.

T3 Delivery: The Argument Women Make for NDT

Standard levothyroxine relies entirely on peripheral conversion of T4 to T3. A subset of women carry variants in the DIO2 gene (encoding type 2 deiodinase) that reduce this conversion efficiency in the brain, potentially explaining persistent fatigue, brain fog, and low mood despite normal serum TSH. Because Armour Thyroid provides preformed T3, some women notice symptomatic improvement. The Hoang et al. Crossover trial published in the Journal of Clinical Endocrinology and Metabolism in 2013 randomized 70 hypothyroid patients to NDT or levothyroxine for 16 weeks each and found that 49 percent preferred NDT vs 19 percent preferring levothyroxine, with no statistically significant difference in most quality-of-life measures, though NDT produced slightly more weight loss. TSH was similar between groups at comparable doses. That trial did not measure liver enzymes as a primary endpoint.

How Hypothyroidism Itself Affects Liver Function

Before attributing any liver enzyme change to Armour Thyroid, you and your clinician need to recognize that untreated or under-treated hypothyroidism is itself a cause of elevated transaminases.

Enzyme Elevations in Hypothyroid State

Overt hypothyroidism can raise alanine aminotransferase (ALT) and aspartate aminotransferase (AST) through reduced hepatic clearance of these enzymes, mitochondrial dysfunction in hepatocytes, and non-alcoholic fatty liver disease (NAFLD) driven by dyslipidemia and insulin resistance. A 2019 analysis found that hypothyroidism was independently associated with a 2.2-fold increased odds of NAFLD after adjusting for metabolic confounders. In clinical practice, you may present with mildly elevated ALT or alkaline phosphatase and a thyroid disorder as the underlying cause, not a liver problem that needs independent workup.

What Happens When Thyroid Replacement Works

Effective thyroid replacement, whether levothyroxine or NDT, generally normalizes mildly elevated liver enzymes. A case series reported in the literature describes women whose ALT normalized within 6 to 12 weeks of reaching euthyroid status. This means the first liver function panel after starting Armour Thyroid may actually show improvement, not harm, especially if you were hypothyroid at baseline.

Does Armour Thyroid Directly Harm the Liver?

At therapeutic doses, direct hepatotoxicity from NDT is rare. There is no established drug-induced liver injury (DILI) signal for porcine desiccated thyroid in the FDA DILI database comparable to that seen with anabolic steroids or certain antifungals.

The Thyrotoxicosis Risk Is Real

The liver risk that does exist with Armour Thyroid is indirect: excess thyroid hormone (thyrotoxicosis) from over-dosing. Thyrotoxicosis raises hepatic oxygen demand, accelerates hepatic glycogen breakdown, and in severe cases can cause centrolobular necrosis. Clinically significant thyrotoxic liver injury is uncommon at typical outpatient NDT doses, but subclinical over-replacement, defined as a suppressed TSH below 0.1 mIU/L, can produce persistent, low-grade enzyme elevation.

Because Armour Thyroid contains T3 in addition to T4, free T3 levels peak sharply one to two hours after a dose. This pharmacokinetic pattern means serum T3 can temporarily enter a supraphysiologic range even when the 24-hour average is appropriate. For women with pre-existing liver disease or cardiovascular risk, that transient spike carries added clinical weight.

Iodine Load from NDT

Porcine thyroid gland contains iodine beyond what the synthetic equivalents carry. High iodine exposure can transiently suppress thyroid function (Wolff-Chaikoff effect) or, paradoxically, trigger thyrotoxicosis in women with nodular goiter. This is not a primary liver concern, but thyrotoxicosis from iodine excess would carry the same downstream hepatic risks described above.

Monitoring Schedule After Starting NDT

| Timepoint | Tests to Order | |-----------|----------------| | Baseline (before starting) | TSH, free T4, free T3, ALT, AST, alkaline phosphatase, lipid panel | | 6-8 weeks after dose change | TSH, free T4, free T3 | | 3-6 months stable | TSH, free T4, free T3, ALT, AST | | Annually (or with symptoms) | Full panel including TBG if on estrogen therapy |

Women's Physiology: How Hormonal Status Changes the Picture

Thyroid hormone metabolism is not static across a woman's life. Estrogen, progesterone, pregnancy, and the hypothalamic-pituitary axis shifts of perimenopause all alter how NDT behaves and how liver function tests should be interpreted. The framework below organizes this by life stage.

Reproductive Years (Ages 18-40)

During the follicular phase of your menstrual cycle, rising estrogen stimulates hepatic TBG production, which can cause total T4 and total T3 to rise even though free hormone levels stay the same. If your clinician orders total rather than free thyroid hormones, this can look like over-replacement and prompt an unnecessary dose reduction.

Women with PCOS have a higher prevalence of Hashimoto's thyroiditis. One meta-analysis found thyroid autoimmunity in approximately 26 percent of women with PCOS compared to around 8 percent in controls. This matters for NDT because autoimmune thyroid disease can fluctuate, and what looks like an adequate NDT dose in one month may produce over-replacement a few months later as the gland transiently releases stored hormone. Liver enzyme surveillance during these fluctuations is reasonable clinical practice.

Trying to Conceive and Fertility Treatment

Hypothyroidism impairs ovulation and implantation. The American Thyroid Association recommends a pre-conception TSH target of <2.5 mIU/L for women planning pregnancy. Ovulation induction with gonadotropins or IVF stimulation protocols raise estrogen dramatically, which in turn raises TBG. This means your NDT dose may need adjustment during fertility treatment, and liver enzymes may shift as estrogen-mediated TBG changes alter thyroid hormone distribution.

Perimenopause

Perimenopause introduces erratic estrogen fluctuations, which means TBG levels become less predictable. A woman stable on a fixed NDT dose for years may find her TSH drifting as estrogen oscillates. At the same time, the liver's metabolic burden increases during perimenopause as insulin resistance and NAFLD prevalence climb. Annual liver function monitoring in perimenopausal women on NDT is sensible, particularly if you also carry metabolic risk factors such as central adiposity or pre-diabetes.

Systemic estrogen therapy (whether oral or transdermal) affects TBG differently. Oral estrogen raises TBG significantly; transdermal estrogen does not. If you start oral hormone therapy while on a stable NDT dose, expect your total thyroid hormone levels to rise and your TSH to drift upward within 4 to 8 weeks, requiring a dose increase. Transdermal estrogen generally does not require a dose adjustment for the same reason.

Postmenopause

After menopause, estrogen levels are low and TBG production falls, which means total thyroid hormone values drop even when free levels are unchanged. Women switching from oral to transdermal estrogen, or stopping hormone therapy entirely, may see their NDT dose become relatively excessive. Annual TSH monitoring is sufficient for most stable postmenopausal women on NDT, but add free T3 if symptoms change.

Pregnancy and Lactation: What You Must Know Before Taking NDT

This is the most safety-critical section if you are pregnant, planning pregnancy, or breastfeeding.

Pregnancy Safety

Armour Thyroid is not contraindicated in pregnancy, and thyroid hormone itself is essential for fetal brain development, particularly in the first trimester before the fetal thyroid begins functioning at around 10 to 12 weeks. The fetus depends entirely on maternal T4 for the first several weeks.

Here is the specific concern with NDT during pregnancy: the American Thyroid Association 2017 guidelines on thyroid disease in pregnancy recommend levothyroxine as the preferred agent, not NDT. The reason is the T3 content of NDT. T3 crosses the placenta poorly, so the preformed T3 in Armour Thyroid does not provide fetal benefit the way maternal T4 does, and the supra-physiologic T3 peaks after each dose carry uncertain fetal risk. Maternal thyrotoxicosis, even subclinical, is associated with adverse pregnancy outcomes including preterm birth and low birth weight.

Dose requirements for thyroid replacement increase by approximately 20 to 50 percent during pregnancy, starting as early as 4 to 6 weeks of gestation, driven by rising TBG, increased renal iodine clearance, and fetal T4 demand. If you are already pregnant and taking NDT, do not stop abruptly. Contact your clinician immediately to discuss switching to levothyroxine or adjusting your dose, with TSH and free T4 targets of TSH <2.5 mIU/L in the first trimester and TSH <3.0 mIU/L in the second and third trimesters per ATA 2017 guidance.

Postpartum and Lactation

Thyroid hormones are present in breast milk at low concentrations, but the amount transferred through human milk from a mother taking replacement doses is considered physiologic and not known to cause adverse effects in nursing infants. Postpartum thyroiditis affects approximately 5 to 10 percent of women in the first year after delivery and can produce transient thyrotoxicosis followed by hypothyroidism. If you are newly diagnosed postpartum and starting thyroid replacement, levothyroxine is again the standard choice. If you were on NDT before pregnancy, the transition back after delivery should involve TSH rechecking within 6 to 8 weeks of resuming your pre-pregnancy dose, because TBG falls quickly after delivery.

Contraception Consideration

NDT is not a teratogen in the way that drugs like isotretinoin or valproate are. You do not need specific contraception requirements solely because of NDT. Adequate thyroid replacement is beneficial for fertility, not harmful. The clinical priority is maintaining euthyroid status rather than a specific contraceptive approach.

Who This Is Right For, and Who Should Reconsider

Women Who May Benefit from NDT

• Women with confirmed or suspected DIO2 polymorphism who report persistent symptoms (fatigue, cognitive slowing, weight resistance) on optimized levothyroxine with normal TSH
• Women whose preference after a shared-decision conversation includes trying a T3-containing preparation
• Women in their reproductive or perimenopausal years with Hashimoto's disease who want a trial of NDT with appropriate monitoring
• Women who have failed multiple levothyroxine brands and report symptom improvement on NDT in prior clinical experience

Women Who Should Use Caution or Choose Alternatives

• Pregnant women: switch to levothyroxine or discuss urgently with your clinician
• Women with atrial fibrillation, osteoporosis, or known cardiovascular disease, because the T3 peaks from NDT carry a higher arrhythmia and bone-loss risk
• Women with pre-existing liver disease, particularly cirrhosis or non-alcoholic steatohepatitis, where altered thyroid hormone metabolism complicates dosing
• Women on oral estrogen therapy: dose adjustments are predictable but add management complexity
• Women with nodular thyroid disease or iodine sensitivity

Interpreting Liver Function Tests While on NDT

A single mildly elevated ALT on NDT does not mean the drug is harming your liver. Before any intervention, your clinician should ask:

1. Is your TSH suppressed, suggesting over-replacement?
2. Did you have elevated liver enzymes before starting NDT (i.e., from hypothyroidism itself)?
3. Do you have other explanations: alcohol, fatty liver, medications such as statins, or viral hepatitis?
4. Is your estrogen status (cycle phase, hormonal contraception, hormone therapy) affecting TBG and making your free hormone levels misleading?

If ALT is more than three times the upper limit of normal and TSH is suppressed, reduce the NDT dose and recheck in 6 to 8 weeks. If ALT is elevated with a normal or high TSH, the liver finding is more likely from under-treatment or an independent cause.

The American Association for the Study of Liver Diseases (AASLD) defines drug-induced liver injury as ALT greater than five times the upper limit of normal or bilirubin greater than two times normal in the context of drug exposure. True NDT-induced DILI meeting these criteria is documented only in case reports involving doses far exceeding therapeutic ranges.

NDT vs. Levothyroxine: What the Evidence Actually Shows

The Hoang et al. Crossover trial remains the most cited head-to-head comparison. Hoang et al., JCEM 2013 demonstrated equivalent TSH suppression and a modest patient-preference signal for NDT without significant differences in lipid profiles, quality of life scores, or adverse events at a sample size of 70. The trial was not powered to detect rare hepatotoxicity events, and liver enzymes were not a primary or secondary endpoint.

A 2019 systematic review in Frontiers in Endocrinology pooled data from four randomized controlled trials comparing T4 plus T3 combination therapy (a pharmacologically similar strategy) with T4 alone and found no significant difference in liver function tests across studies. This does not prove NDT is liver-safe in all circumstances, but it provides indirect reassurance that the T3 component at physiologic doses does not appear to drive hepatotoxicity.

"The evidence does not support superiority of desiccated thyroid extract or combined T4/T3 therapy over levothyroxine monotherapy for most patients with hypothyroidism," states the American Thyroid Association 2014 hypothyroidism guidelines, while acknowledging that some patients may prefer NDT and that the evidence base is limited.

Women have been under-represented in thyroid trials. Most NDT and combination therapy trials have included both sexes without sex-stratified analysis, meaning the data on female-specific responses to NDT, including liver enzyme trends across the menstrual cycle or in the context of estrogen therapy, are extrapolated rather than directly studied. This is a genuine evidence gap.

Practical Dosing Notes for Women

Armour Thyroid is dosed in grains. One grain equals 60 mg of desiccated thyroid and delivers approximately 38 mcg T4 and 9 mcg T3. Most women start at half a grain (30 mg) daily and titrate by half-grain increments every 4 to 6 weeks, guided by TSH and free T3 levels. The target free T3 when stable on NDT is generally the upper half of the reference range, though no randomized trial has established an optimal free T3 target specifically for women.

Take NDT on an empty stomach, 30 to 60 minutes before food, the same as levothyroxine. Calcium supplements, iron, and antacids reduce absorption and should be separated by at least four hours. Coffee and high-fiber foods also impair absorption if consumed simultaneously with the dose.

For women on stable oral estrogen therapy starting NDT, expect a roughly 25 to 30 percent higher total dose requirement compared with women not on oral estrogen, because of TBG-driven increases in bound (inactive) thyroid hormone.

Recheck liver enzymes 3 months after reaching a stable NDT dose, then annually. If you develop new symptoms of jaundice, right upper quadrant pain, or dark urine on NDT at any point, contact your clinician the same day.